Jim Cramer’s 5 Stock Calls, Including Alphabet and Eli Lilly, and Possible Opportunities

In this article, we will look at Jim Cramer’s 5 Stock Calls, Including Alphabet and Eli Lilly, and Possible Opportunities. Please visit Jim Cramer’s 15 Stock Calls, Including Salesforce and Cisco, and Possible Opportunities, if you’d like to see the extended list and methodology behind it.

5. Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer highlighted the company’s billion-dollar drugs and growing businesses, as he stated:

So I’m going to do something completely out of favor and recommend one that we’re buying for the Charitable Trust gingerly as club members know, which is Johnson & Johnson. J&J has 10 commercialized drugs that bring in more than a billion dollars, several more coming, growing medtech business helped by some terrific acquisitions like Shockwave, Abiomed for cardio repair. Meanwhile, J&J’s divesting its prosaic commodity, artificial hips and knees business, something that could further raise its price to earnings multiple, which currently stands at a very low 19 times earnings.

Plus, unlike almost every other drug company besides Lilly, J&J has no big patent expirations. Instead there’s more potentially big drugs on the come. Buy this one slowly because, like the banks, there is very little support for the stock right here. Well, then why start now? Again, because we don’t know when this vicious rotation will end. They take you by surprise.

Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases.